Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Amundi

Amundi lessened its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 12.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 572,912 shares of the company's stock after selling 80,958 shares during the period. Amundi owned about 0.05% of Teva Pharmaceutical Industries worth $12,312,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Smithfield Trust Co grew its stake in shares of Teva Pharmaceutical Industries by 55.7% during the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company's stock worth $50,000 after acquiring an additional 980 shares during the period. Wilmington Savings Fund Society FSB bought a new position in Teva Pharmaceutical Industries in the 3rd quarter valued at $50,000. Venturi Wealth Management LLC purchased a new position in Teva Pharmaceutical Industries during the third quarter worth about $60,000. Ameliora Wealth Management Ltd. purchased a new position in Teva Pharmaceutical Industries in the 4th quarter worth approximately $66,000. Finally, IFP Advisors Inc increased its stake in Teva Pharmaceutical Industries by 96.1% in the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock valued at $88,000 after acquiring an additional 1,960 shares during the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Roberto Mignone sold 286,000 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the sale, the director now directly owns 695,000 shares in the company, valued at approximately $15,296,950. This trade represents a 29.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.55% of the company's stock.

Remove Ads

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE:TEVA traded down $0.09 during midday trading on Friday, hitting $16.38. The company had a trading volume of 6,488,903 shares, compared to its average volume of 12,964,806. The company has a fifty day moving average of $18.28 and a two-hundred day moving average of $18.30. Teva Pharmaceutical Industries Limited has a 12-month low of $12.51 and a 12-month high of $22.80. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The company has a market cap of $18.57 billion, a price-to-earnings ratio of -11.29, a PEG ratio of 1.44 and a beta of 0.82.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, equities research analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. UBS Group decreased their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research note on Thursday, January 30th. StockNews.com lowered Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research report on Friday, March 7th. Barclays decreased their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, January 30th. Piper Sandler boosted their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research report on Friday, January 17th. Finally, Bank of America decreased their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a report on Thursday, March 6th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of "Moderate Buy" and a consensus target price of $23.43.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.